Drugs / FZ-AD004
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05914545 | Jun 2023 → Dec 2026 expected | — | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FZ-AD004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05914545 ↗ |
| Route | Intravenous | “FZ-AD004 is administered via intravenous infusion” NCT05914545 ↗ |